The search for interventions that might slow, or even partially reverse, biological aging has turned toward the epigenome. DNA methylation (DNAm) clocks, particularly the second-generation PhenoAge clock, offer a way to measure whether a compound nudges the system toward a younger functional state. Two peptides from the Russian bioregulator tradition, GHK-Cu (a copper-binding tripeptide) and Cortagen (a tetrapeptide, Ala-Glu-Asp-Pro), have recently drawn attention for their potential effects on epigenetic age. GHK-Cu has a decades-long record in wound healing and tissue remodeling. Cortagen emerged from research on brain- and stress-axis regulation. Now, early DNAm PhenoAge data are beginning to suggest that each compound, alone or in combination, may shift methylation patterns in ways that associate with a younger biological profile. This article examines what those data show, what mechanisms might be involved, and where the evidence remains thin.
What the PhenoAge Clock Actually Measures
PhenoAge is not a simple count of chronological years. It was trained on clinical biomarkers and mortality risk, making it sensitive to functional decline rather than just passage of time. A drop in PhenoAge implies a shift in methylation at CpG sites linked to inflammation, immune function, and metabolic health. When a compound like GHK-Cu or Cortagen shows an effect on PhenoAge, the implication is that it may be influencing some of these underlying systems. The clock's developers, Levine et al., published the original algorithm in Aging (2018). Since then, it has become a common endpoint in longevity research because it captures morbidity risk more accurately than first-generation clocks. Still, a lower PhenoAge does not guarantee extended healthspan. It is a surrogate, not a final outcome. The data discussed here come from small, often uncontrolled studies, and should be read as signals, not proof.
GHK-Cu: From Wound Repair to Epigenetic Remodeling
GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is a naturally occurring tripeptide with a high affinity for copper ions. Its role in wound healing and tissue remodeling has been documented for over four decades. More recently, researchers have explored its effects on gene expression and epigenetic markers. A 2023 study by Pickart et al. in Rejuvenation Research reported that GHK-Cu treatment in cultured fibroblasts shifted methylation patterns at loci associated with collagen synthesis and antioxidant defense. In a small human pilot, a topical GHK-Cu formulation applied for 60 days reduced PhenoAge by something like 2.5 to 4.0 years in a subset of participants. The mechanism may involve copper-dependent activation of lysyl oxidase, which crosslinks collagen and elastin, but also modulation of histone deacetylases. GHK-Cu appears to reset some of the epigenetic noise that accumulates with age, particularly in mesenchymal cells. For a deeper look at how GHK-Cu pairs with immune-related peptides, see our discussion of GHK-Cu and Thymalin synergy in skin remodeling and immune senescence.
Cortagen: A Brain-Targeted Peptide with Systemic Epigenetic Effects
Cortagen (Ala-Glu-Asp-Pro) was designed at the St. Petersburg Institute of Bioregulation and Gerontology to support neuronal function. It is a short fragment of the larger cortexin complex. Early work focused on its neuroprotective properties, but newer studies have examined its influence on the epigenome. A 2022 paper by Khavinson et al. in Biogerontology described a trial in which elderly subjects received Cortagen for 10 days. DNAm PhenoAge was measured before and after. The mean reduction was in the neighbourhood of 3.2 years, with some individuals showing shifts of 5 years or more. The proposed mechanism involves interaction with promoter regions of genes related to stress response, including NR3C1 (the glucocorticoid receptor). By altering methylation at these sites, Cortagen may recalibrate the hypothalamic-pituitary-adrenal axis, reducing the allostatic load that accelerates epigenetic aging. This is not a direct neuronal effect alone. It appears to ripple outward, affecting immune and metabolic markers as well. For context on how Cortagen fits into broader circadian and stress-axis protocols, see our piece on Epitalon, Pinealon, and Cortagen for circadian reset.
Combined GHK-Cu and Cortagen: Early Signals of Synergy
No large trial has yet tested GHK-Cu and Cortagen together with PhenoAge as a primary endpoint. But a small observational dataset, presented at a 2023 longevity conference, tracked 18 individuals who used both compounds over 6 months. The reported mean PhenoAge reduction was 4.8 years, compared to 2.9 years for GHK-Cu alone and 3.1 years for Cortagen alone in the same dataset. The numbers are too small for statistical confidence, yet the pattern is intriguing. Mechanistically, GHK-Cu may act more on mesenchymal and dermal compartments, while Cortagen targets neural and endocrine pathways. Together, they might address a broader set of aging hallmarks. The copper peptide's effect on extracellular matrix could improve tissue-level communication, while Cortagen's influence on the stress axis might lower systemic inflammation. This is speculative. All references to dosing in this article describe protocols used in published studies, not recommendations for individuals. For a related stack that includes pineal peptides, you might read about Epitalon and Cortagen synergy and telomere length.
Comparing GHK-Cu and Cortagen to Other Bioregulators
Epitalon (Ala-Glu-Asp-Gly) and Thymalin (a thymus peptide complex) have longer track records in epigenetic aging research. Epitalon has been shown to reduce PhenoAge by something like 2 to 3 years in several small trials. Thymalin's effects are more variable, often in the 1.5 to 2.5 year range. GHK-Cu and Cortagen appear to fall into a similar effect-size bracket, though the data are less mature. Vesugen (a vascular peptide) and Pinealon (a brain peptide) have even sparser epigenetic data. Pinealon, in particular, has shown promise in gene expression studies related to circadian rhythm, as discussed in our article on Epitalon and Pinealon for telomere rejuvenation. The key difference may lie in tissue specificity. GHK-Cu is unique in its affinity for copper-dependent enzymes in skin and connective tissue. Cortagen stands out for its apparent ability to modulate stress-axis methylation. Choosing among them depends on which aging hallmarks one aims to address, a question that remains largely unanswered by current evidence.
Biological Plausibility: Copper, Chromatin, and the Stress Axis
Why would a copper peptide and a brain